Literature DB >> 24637583

Improving bladder cancer imaging using 3-T functional dynamic contrast-enhanced magnetic resonance imaging.

Huyen T Nguyen1, Kamal S Pohar, Guang Jia, Zarine K Shah, Amir Mortazavi, Debra L Zynger, Lai Wei, Daniel Clark, Xiangyu Yang, Michael V Knopp.   

Abstract

OBJECTIVES: The objective of this study was to assess the capability of T2-weighted magnetic resonance imaging (T2W-MRI) and the additional diagnostic value of dynamic contrast-enhanced MRI (DCE-MRI) using multitransmit 3 T in the localization of bladder cancer.
MATERIALS AND METHODS: This prospective study was approved by the local institutional review board. Thirty-six patients were included in the study and provided informed consent. Magnetic resonance imaging scans were performed with T2W-MRI and DCE-MRI on a 3-T multitransmit system. Two observers (with 12 and 25 years of experience) independently interpreted T2W-MRI before DCE-MRI data (maps of pharmacokinetic parameters) to localize bladder tumors. The pathological examination of cystectomy bladder specimens was used as a reference criteria standard. The McNemar test was performed to evaluate the differences in sensitivity, specificity, and accuracy. Scores of κ were calculated to assess interobserver agreement.
RESULTS: The sensitivity, specificity, and accuracy of the localization with T2W-MRI alone were 81% (29/36), 63% (5/8), and 77% (34/44) for observer 1 and 72% (26/36), 63% (5/8), and 70% (31/44) for observer 2. With additional DCE-MRI available, these values were 92% (33/36), 75% (6/8), and 89% (39/44) for observer 1 and 92% (33/36), 63% (5/8), and 86% (38/44) for observer 2. Dynamic contrast-enhanced MRI significantly (P<0.01) improved the sensitivity and accuracy for observer 2. For the 23 patients treated with chemotherapy, DCE-MRI also significantly (P<0.02) improved the sensitivity and accuracy of bladder cancer localization with T2W-MRI alone for observer 2. Scores of κ were 0.63 for T2W-MRI alone and 0.78 for additional DCE-MRI. Of 7 subcentimeter malignant tumors, 4 (57%) were identified on T2W images and 6 (86%) were identified on DCE maps. Of 11 malignant tumors within the bladder wall thickening, 6 (55%) were found on T2W images and 10 (91%) were found on DCE maps.
CONCLUSIONS: Compared with conventional T2W-MRI alone, the addition of DCE-MRI improved interobserver agreement as well as the localization of small malignant tumors and those within bladder wall thickening.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24637583      PMCID: PMC4326253          DOI: 10.1097/RLI.0000000000000022

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  30 in total

1.  Diffusion tensor imaging (DTI) of the kidney at 3 tesla-feasibility, protocol evaluation and comparison to 1.5 Tesla.

Authors:  Mike Notohamiprodjo; Olaf Dietrich; Wihelm Horger; Annie Horng; Andreas D Helck; Karin A Herrmann; Maximilian F Reiser; Christian Glaser
Journal:  Invest Radiol       Date:  2010-05       Impact factor: 6.016

2.  Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging.

Authors:  G Brix; W Semmler; R Port; L R Schad; G Layer; W J Lorenz
Journal:  J Comput Assist Tomogr       Date:  1991 Jul-Aug       Impact factor: 1.826

3.  Dual-source parallel radiofrequency excitation body MR imaging compared with standard MR imaging at 3.0 T: initial clinical experience.

Authors:  Winfried A Willinek; Jürgen Gieseke; Guido M Kukuk; Michael Nelles; Roy König; Nuschin Morakkabati-Spitz; Frank Träber; Daniel Thomas; Christiane K Kuhl; Hans H Schild
Journal:  Radiology       Date:  2010-09       Impact factor: 11.105

4.  Initial results with (11)C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer.

Authors:  Heiko Schöder; Seng C Ong; Victor E Reuter; Shangde Cai; Eva Burnazi; Guido Dalbagni; Steven M Larson; Bernard H Bochner
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

5.  Interobserver variability limits exact preoperative staging by computed tomography in bladder cancer.

Authors:  Stefan Tritschler; Clarissa Mosler; Derya Tilki; Alexander Buchner; Christian Stief; Anno Graser
Journal:  Urology       Date:  2012-03-23       Impact factor: 2.649

6.  Accuracy of contrast-enhanced ultrasound in the detection of bladder cancer.

Authors:  C Nicolau; L Bunesch; L Peri; R Salvador; J M Corral; C Mallofre; C Sebastia
Journal:  Br J Radiol       Date:  2010-12-01       Impact factor: 3.039

7.  Application of new technology in bladder cancer diagnosis and treatment.

Authors:  Alvin C Goh; Seth P Lerner
Journal:  World J Urol       Date:  2009-02-22       Impact factor: 4.226

8.  Interscanner comparison of dynamic contrast-enhanced MRI in prostate cancer: 1.5 versus 3 T MRI.

Authors:  Metin Sertdemir; Stefan O Schoenberg; Steven Sourbron; Daniel Hausmann; Julia Heinzelbecker; Henrik J Michaely; Dietmar J Dinter; Anja M Weidner
Journal:  Invest Radiol       Date:  2013-02       Impact factor: 6.016

9.  Preoperative staging of locally advanced bladder cancer before radical cystectomy using 3 tesla magnetic resonance imaging with a standardized protocol.

Authors:  Fredrik Liedberg; Pär-Ola Bendahl; Thomas Davidsson; Sigurdur Gudjonsson; Magnus Holmer; Wiking Månsson; Nils-Olof Wallengren
Journal:  Scand J Urol       Date:  2012-09-19       Impact factor: 1.612

Review 10.  Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

Authors:  P S Tofts; G Brix; D L Buckley; J L Evelhoch; E Henderson; M V Knopp; H B Larsson; T Y Lee; N A Mayr; G J Parker; R E Port; J Taylor; R M Weisskoff
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

View more
  8 in total

1.  Effect of parallel radiofrequency transmission on arterial input function selection in dynamic contrast-enhanced 3 Tesla pelvic MRI.

Authors:  Hatim Chafi; Saba N Elias; Huyen T Nguyen; Harry T Friel; Michael V Knopp; BeiBei Guo; Steven B Heymsfield; Guang Jia
Journal:  J Magn Reson Imaging       Date:  2015-06-09       Impact factor: 4.813

2.  Non-invasive quantification of tumour heterogeneity in water diffusivity to differentiate malignant from benign tissues of urinary bladder: a phase I study.

Authors:  Huyen T Nguyen; Zarine K Shah; Amir Mortazavi; Kamal S Pohar; Lai Wei; Guang Jia; Debra L Zynger; Michael V Knopp
Journal:  Eur Radiol       Date:  2016-08-23       Impact factor: 5.315

3.  Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contrast-enhanced (DCE)-MRI pharmacokinetic parameters.

Authors:  Huyen T Nguyen; Guang Jia; Zarine K Shah; Kamal Pohar; Amir Mortazavi; Debra L Zynger; Lai Wei; Xiangyu Yang; Daniel Clark; Michael V Knopp
Journal:  J Magn Reson Imaging       Date:  2014-06-19       Impact factor: 4.813

Review 4.  Recent advances in imaging and understanding interstitial cystitis.

Authors:  Pradeep Tyagi; Chan-Hong Moon; Joseph Janicki; Jonathan Kaufman; Michael Chancellor; Naoki Yoshimura; Christopher Chermansky
Journal:  F1000Res       Date:  2018-11-09

Review 5.  The Role of Imaging in Bladder Cancer Diagnosis and Staging.

Authors:  Samuel J Galgano; Kristin K Porter; Constantine Burgan; Soroush Rais-Bahrami
Journal:  Diagnostics (Basel)       Date:  2020-09-16

6.  A glance at imaging bladder cancer.

Authors:  Ebru Salmanoglu; Ethan Halpern; Edouard J Trabulsi; Sung Kim; Mathew L Thakur
Journal:  Clin Transl Imaging       Date:  2018-05-16

7.  Radiomics-guided therapy for bladder cancer: Using an optimal biomarker approach to determine extent of bladder cancer invasion from t2-weighted magnetic resonance images.

Authors:  Yubing Tong; Jayaram K Udupa; Chuang Wang; Jerry Chen; Sriram Venigalla; Thomas J Guzzo; Ronac Mamtani; Brian C Baumann; John P Christodouleas; Drew A Torigian
Journal:  Adv Radiat Oncol       Date:  2018-05-08

Review 8.  Imaging of Bladder Cancer: Standard Applications and Future Trends.

Authors:  Rasha Taha Abouelkheir; Abdalla Abdelhamid; Mohamed Abou El-Ghar; Tarek El-Diasty
Journal:  Medicina (Kaunas)       Date:  2021-03-01       Impact factor: 2.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.